FGFR3 and neoplasm: The lack of a difference in immune gene expression within the tumour subtype in the presence and absence of FGFR3 mutation in human MIBC could be due to the fact that human studies are based on established tumours, while our study in mouse models investigated the functional effects of FGFR3 along the process of tumour initiation and development, the earlier phases in tumour pathogenesis.